Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) announced on April 1, 2026 it granted inducement awards to 13 new employees under its amended 2024 Inducement Plan. The awards comprised 67,150 RSUs vesting one-third annually over three years and were approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

All equity vesting is conditioned on continued service through vesting dates; awards were granted outside stockholder-approved plans pursuant to the inducement plan adopted by the board in June 2024.

News Market Reaction – NTLA

+1.29%

+1.29% Session close to close

In the Apr 6 session, NTLA gained 1.29%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement reflects standard equity-based hiring practice, with 67,150 RSUs granted to 13 new...

Analysis

This announcement reflects standard equity-based hiring practice, with 67,150 RSUs granted to 13 new employees under the 2024 Inducement Plan, vesting over 3 years per Nasdaq Rule 5635(c)(4). In context, Intellia recently managed major clinical and financing steps, including positive MAGNITUDE developments and at-the-market program expansion. Investors may watch how ongoing equity grants interact with these broader capital and pipeline milestones when assessing longer-term dilution and execution risk.

Key Figures

Inducement RSUs granted: 67,150 shares New employees: 13 Vesting schedule: One-third annually +4 more

7 metrics

Inducement RSUs granted 67,150 shares Time-based RSUs under 2024 Inducement Plan

New employees 13 Employees receiving inducement grants on April 1, 2026

Vesting schedule One-third annually RSUs vest over three years, time-based

Vesting period 3 years Time-based RSU vesting period

Grant date April 1, 2026 Date inducement RSUs were awarded

Plan adoption June 2024 Initial adoption of 2024 Inducement Plan by board

Listing rule Nasdaq 5635(c)(4) Governs inducement equity grants for new employees

Historical Context

5 past events · Latest: Mar 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 06	Inducement grants	Neutral	+3.4%	RSU inducement awards to six new employees under 2024 Inducement Plan.
Mar 03	Clinical data update	Positive	-11.9%	Longer-term HAE data for lonvo-z showed durable attack reduction and control.
Mar 02	Clinical hold lifted	Positive	+12.1%	FDA lifted clinical hold on MAGNITUDE Phase 3 ATTR-CM trial with added safeguards.
Feb 26	Earnings and updates	Positive	+6.4%	Q4/FY25 results with cash of $605.1M and clear HAELO, BLA and MAGNITUDE plans.
Feb 24	Investor conferences	Neutral	+3.2%	Participation in three early March investor conferences with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent fundamentally positive or neutral news has more often aligned with positive price reactions, with one notable divergence on favorable clinical data.

Recent Company History

Over the last several months, Intellia has mixed routine corporate items with major clinical and financing events. An earlier inducement grant on Mar 6, 2026 coincided with a 3.35% gain. Positive longer-term HAE data on Mar 3, 2026 saw a 11.88% decline, while lifting the MAGNITUDE clinical hold on Mar 2, 2026 led to a 12.05% rise. Q4/FY25 results and business updates on Feb 26, 2026 produced a 6.41% gain, and conference participation news on Feb 24, 2026 coincided with a 3.19% move higher.

Key Terms

crisper gene editing, restricted stock units, nasdaq listing rule 5635(c)(4)

3 terms

crisper gene editing medical

"focused on revolutionizing medicine leveraging CRISPR gene editing and other core"

A laboratory technique that acts like precise molecular scissors to cut, remove or change specific parts of DNA inside living cells; it lets scientists alter genes with much greater accuracy than older methods. Investors watch it because successful gene edits can lead to new medicines, agricultural products or diagnostics, while also carrying high research costs, long regulatory reviews, patent disputes and binary clinical trial outcomes that can sharply change a company’s value.

restricted stock units financial

"The inducement grants consisted of time-based restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 67,150 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Contact:

Jason Fredette
Vice President, Investor Relations and Corporate Communications
jason.fredette@intelliatx.com

This press release was published by a CLEAR® Verified individual.

FAQ

What did Intellia (NTLA) grant on April 1, 2026 under the 2024 Inducement Plan?

Intellia granted 67,150 restricted stock units to 13 new employees as inducement awards. According to the company, the RSUs vest one-third annually over three years and were approved under Nasdaq Listing Rule 5635(c)(4).

How do the NTLA inducement RSUs vest and what are the service conditions?

The RSUs vest in three equal annual installments, with one-third vesting each year. According to the company, vesting requires continued service as an employee or service provider through the applicable vesting dates.

Were the NTLA inducement awards granted under existing stockholder-approved plans?

No, the awards were granted outside stockholder-approved plans under Intellia's amended 2024 Inducement Plan. According to the company, the plan was initially adopted by the board in June 2024 and amended thereafter.

Why did Intellia (NTLA) approve inducement grants under Nasdaq Listing Rule 5635(c)(4)?

The grants were approved as a material inducement to employment for new hires. According to the company, the compensation committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement awards from Intellia (NTLA) on April 1, 2026?

Thirteen new employees received inducement grants under the 2024 Inducement Plan. According to the company, the aggregate award size was 67,150 RSUs and vesting is service-based.